Ontogeny of pathogenic CD4 T cells during the initial neuroinflammation in Experimental Autoimmune Encephalomyelitis

• Grant number: 19/16116-4
• Support Opportunities: Regular Research Grants
• Duration: May 01, 2020 - October 31, 2022
• Field of knowledge: Biological Sciences - Immunology - Cellular Immunology
• Principal Investigator: Alessandro dos Santos Farias
• Grantee: Alessandro dos Santos Farias
• Host Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

Our group has been focusing in the essential conditions to the pathogenicity of encephalitogenic T CD4+ cells during the early stage of EAE. Our preliminary results indicate that STAT5/CIS pathway could play an important role after these cells reach the central nervous system. We believe that this pathway could be essential to the conversion of Th17 into IFN³-producing cells, which we have demonstrated to present a cytotoxic activity. In general, the conversion of these cells must be direct related to the reactivation promoted by local APCs in the CNS. In this context, our data indicated that this interaction is mediated by the release of XCL-1 by the CD4+ T lymphocytes, which will recruit XCR-1 APCs. Therefore, in the present proposal, it is our intention to investigate the role of local APCs (specially XCR-1+) and STAT5/CIS pathway to the pathogenic activity of T CD4+ cells infiltrated into the CNS during the very early clinical phase of EAE. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

BRUNETTI, NATALIA S.; DAVANZO, GUSTAVO G.; DE MORAES, DIOGO; FERRARI, ALLAN J. R.; SOUZA, GABRIELA F.; MURARO, STEFANIE PRIMON; KNITTEL, THIAGO L.; BOLDRINI, VINICIUS O.; MONTEIRO, LAUAR B.; VIRGILIO-DA-SILVA, JOO VICTOR; et al. SARS-CoV-2 uses CD4 to infect T helper lymphocytes. eLIFE, v. 12, p. 26-pg., 2023-07-31. (20/04558-0, 15/15626-8, 19/06459-1, 19/04726-2, 19/16116-4, 19/05155-9, 19/13552-8, 16/18031-8, 19/00098-7, 20/04583-4, 16/00194-8, 21/08354-2, 19/17007-4, 19/22398-2, 17/01184-9, 19/14465-1, 20/04579-7, 13/08293-7, 18/14933-2, 17/23920-9, 19/06372-3, 16/24163-4, 16/23328-0, 20/04919-2, 20/04746-0)

BOLDRINI, VINICIUS O.; MARQUES, ANA M.; QUINTILIANO, RAPHAEL P. S.; MORAES, ADRIEL S.; STELLA, CARLA R. A. V.; LONGHINI, ANA LEDA F.; SANTOS, IRENE; ANDRADE, MARILIA; FERRARI, BRENO; DAMASCENO, ALFREDO; et al. ytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patient. FRONTIERS IN IMMUNOLOGY, v. 13, FEB 7 2022. (19/16116-4, 17/21363-5, 14/26431-0, 15/22052-8, 19/06372-3)